Zealand Pharma prices upsized IPO at $17.87

Zealand Pharma, which licenses approved and investigational peptide-based treatments for diabetes, raised $78 million by offering 4.4 million ADSs at $17.87.

Zealand Pharma plans to list on the Nasdaq under the symbol ZEAL. Morgan Stanley and Goldman Sachs acted as lead managers on the deal.

The article Zealand Pharma prices upsized IPO at $17.87 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.